生血宝合剂对白血病化疗后骨髓抑制及生活质量的改善作用

摘要
图/表
参考文献(15)
相关文章 (15)

全文: PDF (0 KB) HTML (34 KB)
输出: BibTeX | EndNote (RIS)

摘要目的探讨生血宝合剂对白血病化疗后骨髓抑制及生活质量的改善作用。方法选取2018年10月～2019年10月我院收治的80例白血病患者作为研究对象，按照随机数字表法将其分为观察组与对照组，每组各40例。对照组患者采取常规化疗方案，观察组患者在对照组的基础上增加生血宝合剂治疗。比较两组患者的骨髓抑制程度、生活质量和血常规检查结果。结果观察组患者的骨髓抑制程度轻于对照组，差异有统计学意义（P＜0.05）。治疗前，两组患者的功能状态（KPS）评分比较，差异无统计学意义（P＞0.05）；治疗后，观察组患者的KPS评分高于对照组，差异有统计学意义（P＜0.05）；观察组患者治疗后的KPS评分高于治疗前，差异有统计学意义（P＜0.05）；对照组患者治疗后的KPS评分高于治疗前，差异有统计学意义（P＜0.05）。治疗前，两组患者的血红蛋白、白细胞和血小板水平比较，差异无统计学意义（P＞0.05）；治疗后，观察组患者的血红蛋白、白细胞和血小板水平均高于对照组，差异有统计学意义（P＜0.05）；观察组患者治疗后的血红蛋白、白细胞和血小板水平均低于治疗前，差异有统计学意义（P＜0.05）；对照组患者治疗后的血红蛋白、白细胞和血小板水平均低于治疗前，差异有统计学意义（P＜0.05）。结论运用生血宝合剂能够有效改善白血病患者化疗后的骨髓抑制作用，提高生活质量。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章

关键词 ：生血宝合剂, 白血病, 化疗, 生活质量

Abstract：Objective To explore the effect of Shengxuebao Mixture on the improvement of bone marrow suppression and quality of life after chemotherapy for leukemia.Methods A total of 80 patients with leukemia who were admitted to our hospital from October 2018 and October 2019 were selected as the subjects.They were divided into the observation group and the control group by the random number table method,with 40 cases in each group.The control group was treated with conventional chemotherapy regimen,the observation group was additionally treated with Shengxuebao Mixture on the basis of the control group.The situation of bone marrow suppression,quality of life and blood test result were compared between the two groups.Results The degree of bone marrow suppression in the observation group was lighter than that in the control group,and the difference was statistically significant (P＜0.05).Before treatment,there was no statistically significant difference in the Karnofsky (KPS) score between the two groups (P＞0.05).After treatment,the KPS score of the observation group was higher than that of the control group,and the difference was statistically significant (P＜0.05).The KPS score of the observation group after treatment was higher than that before treatment,and the difference was statistically significant (P＜0.05).The KPS score of patients in the control group was higher than that before treatment,and the difference was statistically significant (P＜0.05).Before treatment,there were no significant differences in the levels of hemoglobin,white blood cells and platelets between the two groups (P＞0.05).After treatment,the levels of hemoglobin,white blood cells,and platelets of the observation group were higher than those of the control group,and the differences were statistically significant (P＜0.05).The levels of hemoglobin,white blood cells,and platelets of the observation group after treatment were lower than those before treatment,with statistical significances (P＜0.05).The levels of hemoglobin,white blood cells and platelets in the control group after treatment were lower than those before treatment,and the differences were statistically significant (P＜0.05).Conclusion The application of Shengxuebao Mixture can effectively improve the bone marrow suppression and quality of life of patients with leukemia after chemotherapy.

Key words： Shengxuebao Mixture Leukemia Chemotherapy Quality of life

作者简介: 于洁（1984-），女，汉族，陕西宝鸡人，本科，主治医师，主要从事肿瘤内科及血液病的研究和治疗

引用本文:

于洁；李金红. 生血宝合剂对白血病化疗后骨髓抑制及生活质量的改善作用[J]. 中国当代医药, 2020, 27(31): 103-105.
YU Jie LI Jin-hong. Effect of Shengxuebao Mixture on the improvement of bone marrow suppression and quality of life after chemotherapy for leukemia. 中国当代医药, 2020, 27(31): 103-105.

链接本文:

https://www.dangdaiyiyao.com/CN/ 或 https://www.dangdaiyiyao.com/CN/Y2020/V27/I31/103

[1]	中华医学会血液学分会白血病淋巴瘤学组.复发难治性急性髓系白血病中国诊疗指南（2017年版）[J].中华血液学杂志，2017，38（3）：183-184.
[3]	苏秀华，姚剑峰，张桂新，等.异基因造血干细胞移植治疗难治/复发急性髓系白血病的疗效及预后因素分析[J].中华血液学杂志，2017，38（12）：1024-1030.
[5]	陈玲珑，曾献军.急性淋巴细胞白血病化疗相关认知损害的影像学研究进展[J].中国医学影像技术，2018，34（1）：136-139.
[6]	魏沄沄，张元元，甄英姿，等.儿童急性淋巴细胞白血病诱导化疗期导管相关性血栓发病及危险因素分析[J].中华血液学杂志，2017，38（4）：313-317.
[7]	王燕，韩正祥，张敬川.骨髓基质细胞对急性淋巴细胞白血病细胞化疗敏感性的影响[J].中华肿瘤杂志，2017，39（12）：885-890.
[2]	Kim TW，Park SS，Lim JY，et al.Predictive Role of Circulating Immune Cell Subtypes Early after Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Acute Leukemia[J].Int J Stem Cells，2018，12（1）：73-83.
[4]	Gruber TA，Zwaan CM.Central nervous system disease in pediatric acute myeloid leukemia[J].Pediatr Blood Cancer，2017，64（12）：1279-1282.
[8]	付海霞，黄晓军.单倍型造血干细胞移植治疗非恶性血液病研究进展[J].中华血液学杂志，2018，39（8）：691-696.
[9]	任欣，赵婷，王婧，等.成人急性髓系白血病患者获得早期治疗反应的影响因素分析[J].中华血液学杂志，2017，38（10）：869-875.
[10]	张亮，陈立军，赵立，等.生血宝合剂治疗苹果酸舒尼替尼骨髓抑制的疗效观察[J].军事医学，2013，37（4）：299-300，310.
[11]	贡强君，李卫玉，应露婷.生血宝合剂减轻晚期肺癌患者化疗后骨髓抑制28例[J].江西中医药，2017，48（8）：52-53.
[12]	张欢，王会平，陶千山，等.化疗后CIK 细胞序贯治疗5例老年急性髓系白血病患者疗效评价[J].安徽医科大学学报，2017，52（3）：412-416.
[13]	訾建杰.生血宝合剂治疗肿瘤化疗后贫血的疗效观察[J].国际老年医学杂志，2018，39（3）：145-148.
[14]	易小兰，杨华，张飞飞，等.生血宝合剂的多成分HPLC指纹图谱[J].中国实验方剂学杂志，2016，22（1）：57-60.
[15]	张洁，李巧敏，杨秀丽.生血宝合剂治疗缺铁性贫血的临床疗效[J].世界临床医学，2019，13（1）：59，61.